Literature DB >> 9580228

p21WAF1 mutation is not a predominant alteration in pediatric bone tumors.

A Patiño-García1, E Sotillo-Piñeiro, L Sierrasesúmaga-Ariznabarreta.   

Abstract

The molecular events leading to the development of pediatric bone tumors are not clear to date, but abnormal cell cycle progression has been reported in a wide variety of human tumors due to the alteration of several tumor suppressor genes. We have analyzed 55 bone sarcoma samples from pediatric patients to test the possibility that they harbor mutations in the p21WAF1 tumor suppressor gene. Mutation analysis was performed through denaturing gradient gel electrophoresis analysis of exon 2 of the gene and consequent cycle sequencing of the altered fragments. No mutations affecting the coding regions of the p21WAF1 were found. Nevertheless, we found genetic polymorphisms in nine of the samples analyzed. We conclude that p21WAF1 mutations do not play an important role in the development of this kind of pediatric malignancy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9580228     DOI: 10.1203/00006450-199803000-00014

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  5 in total

1.  Expression of Smad4, TGF-βRII, and p21waf1 in esophageal squamous cell carcinoma tissue.

Authors:  Hui Cheng; Cheng Chen; L U Liu; N A Zhan; Benhui Li
Journal:  Oncol Lett       Date:  2015-04-23       Impact factor: 2.967

Review 2.  p21 in cancer: intricate networks and multiple activities.

Authors:  Tarek Abbas; Anindya Dutta
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

Review 3.  Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy.

Authors:  Shogo Ohkoshi; Masahiko Yano; Yasunobu Matsuda
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

4.  Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.

Authors:  L J Valente; S Grabow; C J Vandenberg; A Strasser; A Janic
Journal:  Oncogene       Date:  2015-12-07       Impact factor: 9.867

5.  Formulation of Small Activating RNA Into Lipidoid Nanoparticles Inhibits Xenograft Prostate Tumor Growth by Inducing p21 Expression.

Authors:  Robert F Place; Ji Wang; Emily J Noonan; Rachel Meyers; Muthiah Manoharan; Klaus Charisse; Rick Duncan; Vera Huang; Xiaoling Wang; Long-Cheng Li
Journal:  Mol Ther Nucleic Acids       Date:  2012-03-27       Impact factor: 10.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.